RAPP — Rapport Therapeutics Share News
0.000.00%
Last trade - 00:00US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
U.S. STOCKS ON THE MOVE-Vicor, Equifax, American Electric Power
U.S. STOCKS ON THE MOVE-Northrop Grumman, Hasbro, GE Aerospace
Rapport surges as bipolar mania drug succeeds mid-stage trial
Brief: Rapport Therapeutics Announces Positive Topline Results From Its Phase 2 Trial Of Rap-219 For The Treatment Of Bipolar Mania
Rapport Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results
U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems
U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge
Rapport Therapeutics rises on granting China rights for epilepsy drug
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Lowe's, TJX Companies, Target
U.S. STOCKS ON THE MOVE-DoorDash, gold and silver miners
BTIG turns bullish on biotech sector, sees 2026 as 'banner year'
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
U.S. RESEARCH ROUNDUP-Chewy, Phillips 66, Vimeo
Rapport Therapeutics slips after $250 mln equity raise